Language:
  
[Sign in] [Register]   

EIAab logo

Index > Protein center > TGFBR1(Gene name) > Human
  • Add your favorite
  • TGFBR1 (Gene name),
  • TGF-beta receptor type-1 (Protein name ),  TGFR1_HUMAN from NCBI database.
  • top
  • Come back to page head.
  • |
  • General Annotation
  • |
  • Antigen Annotation
  • |
  • 3D
  • |
  • Predicted Eptitope
  • |
  • Vaild Sequence
  • |
  • Related Databases
  • |
  • Feedback
  • Gene name:
    TGFBR1(ALK5;SKR4);
    Protein name:
    TGF-beta receptor type-1(TGFR-1);
    Alternative:
    Activin receptor-like kinase 5(ALK-5;ALK5);Activin A receptor type II-like protein kinase of 53kD;TGF-beta type I receptor;Serine/threonine-protein kinase receptor R4(SKR4);Transforming growth factor-beta receptor type I(TGF-beta receptor type I;TbetaR-I);
    Organism:
    Human (Homo sapiens). 
    General Annotation
    Sub Unit:
    Homodimer; in the endoplasmic reticulum but also at the cell membrane. Heterohexamer; TGFB1, TGFB2 and TGFB3 homodimeric ligands assemble a functional receptor composed of two TGFBR1 and TGFBR2 heterodimers to form a ligand-receptor heterohexamer. The respective affinity of TGBRB1 and TGFBR2 for the ligands may modulate the kinetics of assembly of the receptor and may explain the different biological activities of TGFB1, TGFB2 and TGFB3. Interacts with CD109; inhibits TGF-beta receptor activation in keratinocytes. Interacts with RBPMS. Interacts (unphosphorylated) with FKBP1A; prevents TGFBR1 phosphorylation by TGFBR2 and stabilizes it in the inactive conformation. Interacts with SMAD2, SMAD3 and ZFYVE9; ZFYVE9 recruits SMAD2 and SMAD3 to the TGF-beta receptor. Interacts with TRAF6 and MAP3K7; induces MAP3K7 activation by TRAF6. Interacts with PAR6A; involved in TGF-beta induced epithelial to mesenchymal transition. Interacts with SMAD7, NEDD4L, SMURF1 and SMURF2; SMAD7 recruits NEDD4L, SMURF1 and SMURF2 to the TGF-beta receptor.
    Function:
    Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. For instance, TGFBR1 induces TRAF6 autoubiquitination which in turn results in MAP3K7 ubiquitination and activation to trigger apoptosis. Also regulates epithelial to mesenchymal transition through a SMAD-independent signaling pathway through PAR6A phosphorylation and activation.
    Subcellular Location:
    Cell membrane Single-pass type I membrane protein Cell junction tight junction
    Protein Attributes:
    Sequence length:
    503
    Sequence:
    50:
    MEAAVAAPRP | RLLLLVLAAA | AAAAAALLPG | ATALQCFCHL | CTKDNFTCVT | 
    100:
    DGLCFVSVTE | TTDKVIHNSM | CIAEIDLIPR | DRPFVCAPSS | KTGSVTTTYC | 
    150:
    CNQDHCNKIE | LPTTVKSSPG | LGPVELAAVI | AGPVCFVCIS | LMLMVYICHN | 
    200:
    RTVIHHRVPN | EEDPSLDRPF | ISEGTTLKDL | IYDMTTSGSG | SGLPLLVQRT | 
    250:
    IARTIVLQES | IGKGRFGEVW | RGKWRGEEVA | VKIFSSREER | SWFREAEIYQ | 
    300:
    TVMLRHENIL | GFIAADNKDN | GTWTQLWLVS | DYHEHGSLFD | YLNRYTVTVE | 
    350:
    GMIKLALSTA | SGLAHLHMEI | VGTQGKPAIA | HRDLKSKNIL | VKKNGTCCIA | 
    400:
    DLGLAVRHDS | ATDTIDIAPN | HRVGTKRYMA | PEVLDDSINM | KHFESFKRAD | 
    450:
    IYAMGLVFWE | IARRCSIGGI | HEDYQLPYYD | LVPSDPSVEE | MRKVVCEQKL | 
    500:
    RPNIPNRWQS | CEALRVMAKI | MRECWYANGA | ARLTALRIKK | TLSQLSQQEG | 
    503:
    IKM
    3D Structure:
    N/A
    Predicted Eptitope:
    Please Sign in.
    EIAab Sequence  Vaild Sequence:
    Please Sign in.
    Related Databases
    UniGene:
    MIM:
    KEGG:
    SMR:
    String:
    Pfam:
    Uniprot:
     
    FOR
    ELISA Kit for Human TGFR-1
    Cat.:
    E8813m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    ELISA Kit for Human TGFR-1
    Cat.:
    E8813r
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human TGFR-1
    Cat.:
    E8813h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human TGFR-1
    Cat.:
    E8813p
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    ELISA Kit for Human TGFR-1
    Cat.:
    E8813b
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    CLIA Kit for Human TGFR-1
    Cat.:
    U8813h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    CLIA Kit for Human TGFR-1
    Cat.:
    U8813b
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    CLIA Kit for Human TGFR-1
    Cat.:
    U8813m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    CLIA Kit for Human TGFR-1
    Cat.:
    U8813p
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    CLIA Kit for Human TGFR-1
    Cat.:
    U8813r
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Polyclonal Antibody for Human TGFR-1
    Polyclonal Antibody for Human TGFR-1
    Cat.:
    P8813Rb-m
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Polyclonal Antibody for Human TGFR-1
    Polyclonal Antibody for Human TGFR-1
    Polyclonal Antibody for Human TGFR-1
    Cat.:
    P8813Rb-h
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Monoclonal Antibody for Human TGFR-1
    Monoclonal Antibody for Human TGFR-1
    Monoclonal Antibody for Human TGFR-1
    Monoclonal Antibody for Human TGFR-1
    Monoclonal Antibody for Human TGFR-1
    Protein for Human TGFR-1
    Protein for Human TGFR-1
    Protein for Human TGFR-1
    Protein for Human TGFR-1
    Protein for Human TGFR-1

    R&D Technical Data
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

    s

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Precision
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

    Intra-assay Precision (Precision within an assay):Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

    Intra-Assay CV: ≤3.9%

    Inter-assay Precision (Precision between assays):Three samples of known concentration were tested in five separate assays to assess inter-assay precision.

    Inter-Assay CV: ≤7.7%

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Recovery
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

    Recovery was determined by spiking various levels of ACE into serum and plasma .

    Sample Type

    Average(%)

    Recovery Range(%)

    Serum

    99

    91-103

    Plasma

    98

    93-106

     

     

     

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Linearity
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.

     

    The linearity of the kit was assayed by testing samples spiked with appropriate concentration of ACE and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.  

     

    Sample

    1:2

    1:4

    1:8

    1:16

    serum(n=5)

    92-105%

    90-101%

    95-105%

    92-109%

    EDTA plasma(n=5)

    89-95%

    93105%

    89-94%

    90-106%

    heparin plasma(n=5)

    93-104%

     

    94-110%

    101-111%

    91-110%

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    References
    1. 1.
      "Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor."
      Franzen P. , ten Dijke P. , Ichijo H. , Yamashita H. , Schulz P. , Heldin C.-H. , Miyazono K.
      Cell75:681-692(1993) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)
    2. 2.
      "Cloning and genomic organization of the human transforming growth factor-beta type I receptor gene."
      Vellucci V.F. , Reiss M.
      Genomics46:278-283(1997) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]
    3. 3.
      "The genomic structure of the gene encoding the human transforming growth factor beta type I receptor."
      Lynch M.A. , Song H. , DeGroff V.L. , Alam K.Y. , Adams E.M. , Weghorst C.M.
      Submitted (1997-11) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]
    4. 4.
      NIEHS SNPs program
      Submitted (2003-12) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]
    5. 5.
      "DNA sequence and analysis of human chromosome 9."
      Humphray S.J. , Oliver K. , Hunt A.R. , Plumb R.W. , Loveland J.E. , Howe K.L. , Andrews T.D. , Searle S. , Hunt S.E. , Scott C.E. , Jones M.C. , Ainscough R. , Almeida J.P. , Ambrose K.D. , Ashwell R.I.S. , Babbage A.K. , Babbage S. , Bagguley C.L. , more...
      Nature429:369-374(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
    6. 6.
      "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."
      The MGC Project Team
      Genome Res.14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3)
      tissue: Placenta.
    7. 7.
      "Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract."
      Pasche B. , Luo Y. , Rao P.H. , Nimer S.D. , Dmitrovsky E. , Caron P. , Luzzatto L. , Offit K. , Cordon-Cardo C. , Renault B. , Satagopan J.M. , Murty V.V. , Massague J.
      Cancer Res.58:2727-2732(1998) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PROTEIN SEQUENCE OF 34-40;SIGNAL SEQUENCE CLEAVAGE SITE;GLYCOSYLATION;CHARACTERIZATION OF VARIANT TGFBR1*6A ALA-24--26-ALA DEL;VARIANT TGFBR1*10A ALA-26 INS
    8. 8.
      "Alternative splicing of TGF-betas and their high-affinity receptors T beta RI, T beta RII and T beta RIII (betaglycan) reveal new variants in human prostatic cells."
      Konrad L. , Scheiber J.A. , Volck-Badouin E. , Keilani M.M. , Laible L. , Brandt H. , Schmidt A. , Aumuller G. , Hofmann R.
      BMC Genomics8:318-318(2007) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2);NUCLEOTIDE SEQUENCE [MRNA] OF 61-155 (ISOFORM 1);ALTERNATIVE SPLICING
      tissue: Prostate.
    9. 9.
      Konrad L.
      Submitted (2011-03) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: SEQUENCE REVISION (ISOFORM 1)
    10. 10.
      "GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex."
      Wieser R. , Wrana J.L. , Massague J.
      EMBO J.14:2199-2208(1995) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION;PHOSPHORYLATION AT THR-185; THR-186; SER-187; SER-189 AND SER-191 BY TGFBR2;SUBCELLULAR LOCATION;SUBUNIT;MUTAGENESIS OF 185-THR-THR-186; SER-187; SER-189; SER-191; THR-200 AND THR-204
    11. 11.
      "MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma."
      Eppert K. , Scherer S.W. , Ozcelik H. , Pirone R. , Hoodless P. , Kim H. , Tsui L.-C. , Bapat B. , Gallinger S. , Andrulis I.L. , Thomsen G.H. , Wrana J.L. , Attisano L.
      Cell86:543-552(1996) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION IN PHOSPHORYLATION OF SMAD2
    12. 12.
      "MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling."
      Macias-Silva M. , Abdollah S. , Hoodless P.A. , Pirone R. , Attisano L. , Wrana J.L.
      Cell87:1215-1224(1996) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH SMAD2;FUNCTION IN PHOSPHORYLATION OF SMAD2;FUNCTION IN TRANSCRIPTION REGULATION
    13. 13.
      "Mechanism of TGFbeta receptor inhibition by FKBP12."
      Chen Y.G. , Liu F. , Massague J.
      EMBO J.16:3866-3876(1997) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH FKBP1A;ENZYME REGULATION;MUTAGENESIS OF LEU-193 AND PRO-194
    14. 14.
      "TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4."
      Nakao A. , Imamura T. , Souchelnytskyi S. , Kawabata M. , Ishisaki A. , Oeda E. , Tamaki K. , Hanai J. , Heldin C.H. , Miyazono K. , ten Dijke P.
      EMBO J.16:5353-5362(1997) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH SMAD3
    15. 15.
      "TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling."
      Abdollah S. , Macias-Silva M. , Tsukazaki T. , Hayashi H. , Attisano L. , Wrana J.L.
      J. Biol. Chem.272:27678-27685(1997) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH SMAD2;FUNCTION IN PHOSPHORYLATION OF SMAD2;FUNCTION IN TRANSCRIPTION REGULATION
    16. 16.
      "SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor."
      Tsukazaki T. , Chiang T.A. , Davison A.F. , Attisano L. , Wrana J.L.
      Cell95:779-791(1998) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH ZFYVE9
    17. 17.
      "Oligomeric structure of type I and type II transforming growth factor beta receptors: homodimers form in the ER and persist at the plasma membrane."
      Gilboa L. , Wells R.G. , Lodish H.F. , Henis Y.I.
      J. Cell Biol.140:767-777(1998) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: HOMODIMERIZATION;SUBCELLULAR LOCATION
    18. 18.
      "Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF-beta receptor for degradation."
      Kavsak P. , Rasmussen R.K. , Causing C.G. , Bonni S. , Zhu H. , Thomsen G.H. , Wrana J.L.
      Mol. Cell6:1365-1375(2000) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH SMAD7 AND SMURF2;PROTEASOMAL AND LYSOSOMAL DEGRADATION
    19. 19.
      "Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation."
      Ebisawa T. , Fukuchi M. , Murakami G. , Chiba T. , Tanaka K. , Imamura T. , Miyazono K.
      J. Biol. Chem.276:12477-12480(2001) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH SMAD7 AND SMURF1;PROTEASOMAL DEGRADATION
    20. 20.
      "TLP, a novel modulator of TGF-beta signaling, has opposite effects on Smad2- and Smad3-dependent signaling."
      Felici A. , Wurthner J.U. , Parks W.T. , Giam L.R. , Reiss M. , Karpova T.S. , McNally J.G. , Roberts A.B.
      EMBO J.22:4465-4477(2003) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH VPS39
    21. 21.
      "NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor."
      Kuratomi G. , Komuro A. , Goto K. , Shinozaki M. , Miyazawa K. , Miyazono K. , Imamura T.
      Biochem. J.386:461-470(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH NEDD4L;UBIQUITINATION
    22. 22.
      "Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity."
      Ozdamar B. , Bose R. , Barrios-Rodiles M. , Wang H.R. , Zhang Y. , Wrana J.L.
      Science307:1603-1609(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION IN EPITHELIAL TO MESENCHYMAL TRANSITION;SUBCELLULAR LOCATION;INTERACTION WITH PARD6A;FUNCTION IN PHOSPHORYLATION OF PARD6A
    23. 23.
      "Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes."
      Finnson K.W. , Tam B.Y.Y. , Liu K. , Marcoux A. , Lepage P. , Roy S. , Bizet A.A. , Philip A.
      FASEB J.20:1525-1527(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION IN CELLULAR GROWTH INHIBITION;INTERACTION WITH CD109
    24. 24.
      "Potentiation of Smad-mediated transcriptional activation by the RNA-binding protein RBPMS."
      Sun Y. , Ding L. , Zhang H. , Han J. , Yang X. , Yan J. , Zhu Y. , Li J. , Song H. , Ye Q.
      Nucleic Acids Res.34:6314-6326(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH RBPMS
    25. 25.
      "The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner."
      Sorrentino A. , Thakur N. , Grimsby S. , Marcusson A. , von Bulow V. , Schuster N. , Zhang S. , Heldin C.H. , Landstrom M.
      Nat. Cell Biol.10:1199-1207(2008) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION IN APOPTOSIS;INTERACTION WITH TRAF6 AND MAP3K7
    26. 26.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: REVIEW ON PROCESSES REGULATED BY THE TGF-BETA CYTOKINES
    27. 27.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-165;IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
    28. 28.
      "USP15 stabilizes TGF-beta receptor I and promotes oncogenesis through the activation of TGF-beta signaling in glioblastoma."
      Eichhorn P.J. , Rodon L. , Gonzalez-Junca A. , Dirac A. , Gili M. , Martinez-Saez E. , Aura C. , Barba I. , Peg V. , Prat A. , Cuartas I. , Jimenez J. , Garcia-Dorado D. , Sahuquillo J. , Bernards R. , Baselga J. , Seoane J.
      Nat. Med.18:429-435(2012) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: UBIQUITINATION;DEUBIQUITINATION BY USP15
    29. 29.
      "Extracellular domain of type I receptor for transforming growth factor-beta: molecular modelling using protectin (CD59) as a template."
      Jokiranta T.S. , Tissari J. , Teleman O. , Meri S.
      FEBS Lett.376:31-36(1995) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: 3D-STRUCTURE MODELING OF 34-114
    30. 30.
      "Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12."
      Huse M. , Chen Y.-G. , Massague J. , Kuriyan J.
      Cell96:425-436(1999) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 162-503 IN COMPLEX WITH FKBP1A
    31. 31.
      "The TGF beta receptor activation process: an inhibitor- to substrate-binding switch."
      Huse M. , Muir T.W. , Xu L. , Chen Y.-G. , Kuriyan J. , Massague J.
      Mol. Cell8:671-682(2001) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 162-503;PHOSPHORYLATION;INTERACTION WITH SMAD2 AND FKBP1A
    32. 32.
      "Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain."
      Sawyer J.S. , Beight D.W. , Britt K.S. , Anderson B.D. , Campbell R.M. , Goodson T. Jr. , Herron D.K. , Li H.-Y. , McMillen W.T. , Mort N. , Parsons S. , Smith E.C.R. , Wagner J.R. , Yan L. , Zhang F. , Yingling J.M.
      Bioorg. Med. Chem. Lett.14:3581-3584(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 175-500 IN COMPLEX WITH SYNTHETIC INHIBITOR
    33. 33.
      "Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors."
      Gellibert F. , Woolven J. , Fouchet M.-H. , Mathews N. , Goodland H. , Lovegrove V. , Laroze A. , Nguyen V.-L. , Sautet S. , Wang R. , Janson C. , Smith W. , Krysa G. , Boullay V. , De Gouville A.-C. , Huet S. , Hartley D.
      J. Med. Chem.47:4494-4506(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 201-503 IN COMPLEX WITH SYNTHETIC INHIBITOR
    34. 34.
      "Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding."
      Groppe J. , Hinck C.S. , Samavarchi-Tehrani P. , Zubieta C. , Schuermann J.P. , Taylor A.B. , Schwarz P.M. , Wrana J.L. , Hinck A.P.
      Mol. Cell29:157-168(2008) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 33-111 IN COMPLEX WITH TGFBR2 AND TGFB3;DISULFIDE BONDS
    35. 35.
      "Ternary complex of transforming growth factor-beta1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily."
      Radaev S. , Zou Z. , Huang T. , Lafer E.M. , Hinck A.P. , Sun P.D.
      J. Biol. Chem.285:14806-14814(2010) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 31-115 IN COMPLEX WITH TGFBR2 AND TGFB1;RECEPTOR AFFINITY FOR LIGANDS;DISULFIDE BONDS
    36. 36.
      "TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies."
      Kaklamani V.G. , Hou N. , Bian Y. , Reich J. , Offit K. , Michel L.S. , Rubinstein W.S. , Rademaker A. , Pasche B.
      J. Clin. Oncol.21:3236-3243(2003) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: ANALYSIS OF VARIANT TGFBR1*6A ALA-24--26-ALA DEL IN CANCER RISK
    37. 37.
      "No major association between TGFBR1*6A and prostate cancer."
      Kaklamani V.G. , Baddi L. , Rosman D. , Liu J. , Ellis N. , Oddoux C. , Ostrer H. , Chen Y. , Ahsan H. , Offit K. , Pasche B.
      BMC Genet.5:28-28(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: ANALYSIS OF VARIANT TGFBR1*6A ALA-24--26-ALA DEL IN PROSTATE CANCER
    38. 38.
      "A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2."
      Loeys B.L. , Chen J. , Neptune E.R. , Judge D.P. , Podowski M. , Holm T. , Meyers J. , Leitch C.C. , Katsanis N. , Sharifi N. , Xu F.L. , Myers L.A. , Spevak P.J. , Cameron D.E. , De Backer J.F. , Hellemans J. , Chen Y. , Davis E.C. , more...
      Nat. Genet.37:275-281(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS LDS1 ILE-200; ARG-318; GLY-400 AND PRO-487
    39. 39.
      "TGFBR1(*)6A is not associated with prostate cancer in men of European ancestry."
      Suarez B.K. , Pal P. , Jin C.H. , Kaushal R. , Sun G. , Jin L. , Pasche B. , Deka R. , Catalona W.J.
      Prostate Cancer Prostatic Dis.8:50-53(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: ANALYSIS OF VARIANT TGFBR1*6A ALA-24--26-ALA DEL IN PROSTATE CANCER
    40. 40.
      "FBN1, TGFBR1, and the Marfan-craniosynostosis/mental retardation disorders revisited."
      Ades L.C. , Sullivan K. , Biggin A. , Haan E.A. , Brett M. , Holman K.J. , Dixon J. , Robertson S. , Holmes A.D. , Rogers J. , Bennetts B.
      Am. J. Med. Genet. A140:1047-1058(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT LDS1 LEU-241
    41. 41.
      "Identification and in silico analyses of novel TGFBR1 and TGFBR2 mutations in Marfan syndrome-related disorders."
      Matyas G. , Arnold E. , Carrel T. , Baumgartner D. , Boileau C. , Berger W. , Steinmann B.
      Hum. Mutat.27:760-769(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS LDS1 LEU-241 AND GLN-487;VARIANT HIS-267
    42. 42.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS LDS1 GLU-232; TRP-487; PRO-487 AND GLN-487
    43. 44.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT [LARGE SCALE ANALYSIS] VAL-139
    44. 45.
      "Loeys-Dietz syndrome type I and type II: clinical findings and novel mutations in two Italian patients."
      Drera B. , Ritelli M. , Zoppi N. , Wischmeijer A. , Gnoli M. , Fattori R. , Calzavara-Pinton P.G. , Barlati S. , Colombi M.
      Orphanet J. Rare Dis.4:24-24(2009) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT LDS1 GLY-351
    45. 46.
      "Clinical features and genetic analysis of Korean patients with Loeys-Dietz syndrome."
      Yang J.H. , Ki C.S. , Han H. , Song B.G. , Jang S.Y. , Chung T.Y. , Sung K. , Lee H.J. , Kim D.K.
      J. Hum. Genet.57:52-56(2012) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS LDS1 TYR-266; ILE-375 AND GLN-487
    46. 47.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS MSSE TYR-41; SER-45; ARG-52 AND LEU-83
    Product Feedback Wall
    Hot Genes
    Atf2 ASPRO ACE ALCAM C19orf80 Trap1a KSR2 Gdf5
    Top Searches
    Ubiquitin-protein ligase Ubiquitin ELISA metalloproteinase Tumor necrosis Asprosin TRAP1A Alpha
    Why choose EIAAB
    Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
    Further Information
    About us Protein center Bank account Distributors Terms & Conditions Career eiaab.cn

    Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab         Email:eiaab@eiaab.com

    Twitter